drugset / Trial / NCT00698555
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the immunogenicity and safety of different formulations of the candidate HBV-MPL vaccine administered according to a 2-dose schedule and compare it to that of Engerix™-B administered according to a 3-dose schedule in order to determine the optimal dose of each component of the candidate HBV-MPL vaccine when administered at 0 and 6 months
Timeline
- Start
- 1997-03
- Primary completion
- 1998-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine | Vaccine | — | Intramuscular |